急性心肌梗塞患者血清唾液酸含量测定

本文测定了５０例正常人，３２例急性心肌梗塞，５４例冠心病无梗塞者血清ＳＡ水平，结果表明，急性心肌梗塞组血清ＳＡ水平与冠心病无梗塞组及正常人相比，具显著性差异，可能与心肌梗塞造成心肌细胞受损所致使细胞表面成份释放入血有关，所以血清ＳＡ测定可提供一新的心肌梗塞诊断依据。     

生物学标志在产肠毒素性大肠埃希菌同源克隆鉴定中的应用

目的研究多方法、多生物学标志在产肠毒素性大肠埃希菌同源克隆鉴定中的作用。方法在毒力基因检测和分型基础上，首次采用质粒分析法结合多位点酶电泳法，对ＥＴＥＣ同源克隆进行了综合研究。结果７个毒力基因型的２０６株散发ＥＴＥＣ菌株经质粒图谱分型后，共可分成９３个质粒型，有１４０株ＥＴＥＣ具有独特的基因型；进一步用多位点酶电泳分型，２０６株ＥＴＥＣ可被分成１４８个ＥＴ型，３种方法综合，共有１９０株ＥＴＥＣ具有独特的基因型。结论多方法、多生物学标志在同源克隆鉴定中能提供更多、更可靠的信息。     

双抗体夹心法检测胆管癌患者血清中胆管癌相关抗原的临床意义

胆管癌相关抗原（ＣＣＲＡ）是我们从人胆管癌组织中提取的一种新的肿瘤标志物。建立了检测ＣＣＲＡ的ＥＬＩＳＡ方法，检测了４０例正常人及２６８例良恶性疾病病人血清的ＣＣＲＡ浓度，后者包括胆管癌３６例、原发性肝癌４０例、胰腺癌２６例、胃癌３１例、结直肠癌３４例、肺癌１７例、肝硬变２０例、胆石症４０例及胃溃疡２４例。结果显示：４０例正常对照组的血清ＣＣＲＡ浓度为（１４．３８±７．３４）μｇ／ｍｌ（ｘ±ｓ），正常上限为２８．９５μｇ／ｍｌ（ｘ＋２ｓ）；血清ＣＣＲＡ诊断胆管癌的敏感性是７７．７８％，明显高于其它肿瘤组（０～２５）％（Ｐ＜０．００１），特异性是（７５～１００）％。认为对于胆管癌的诊断，ＣＣＲＡ可能是一种较特异的肿瘤相关抗原。     

Development of Activity Assays for High-Volume Evaluation of Human Immunodeficiency Virus (HIV) Protease Inhibitors in Rat Serum: Results with Ditekiren

We showed previously that a commercially available synthetic tetradecapeptide, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser, produces authentic angiotensin I (Ang I) upon incubation with the HIV-1 protease (S. K. Sharma et al., Anal. Biochem. 198:363, 1991). Therefore, we developed an Ang-I based activity assay for HIV protease inhibitors based on the technology developed earlier (M. J. Ruwart et al., Pharm. Res. 7:407, 1990; S. K. Sharma et al., Anal. Biochem. 186:24, 1990) for tracking renin inhibitors in rat sera. Ditekiren was either extracted from sera with ethyl acetate or assayed after the interfering substances in sera were precipitated with acetonitrile. Purified recombinant HIV-1 protease was added to extracted rat serum and the enzymatic reaction was initiated in the presence of the tetradecapeptide substrate. The inhibition of Ang I production was measured by a commercially available RIA kit. The cleanup methodology also enabled a commercially available Proteinase Scintillation Proximity Assay (SPA, Amersham) to quantify ditekiren in rat serum through the addition of recombinant HIV-1 protease and cleavage of substrate from SPA beads. Results were confirmed by HPLC or by the renin assay for ditekiren, which inhibits both aspartyl proteases. These technologies should prove useful for assessing serum levels of HIV protease inhibitors in rat.     

Effect of haemodialysis on serum levels of tumour markers in patients with end-stage renal failure

SUMMARY: We studied the effect of haemodialysis on the serum levels of tumour markers in 78 patients, 49 men and 29 women with a mean age of 61 ± 2 years, who had been undergoing haemodialysis for 39 ± 10 months. No patient had any clinical evidence of malignancy. Serum values of carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), squamous-cell-carcinoma-related antigen (SCC), neuron-specific enolase (NSE), tissue polypeptide antigen (TPA), CA 15-3, CA 19–9, and among males prostate-specific antigen (PSA) were determined before and after dialysis. Postdialysis values, after being corrected for haemoconcentration, were compared with predialysis values. A significant increase of 32% was observed in NSE levels ( P <0.001) and of 21% in CA 15-3 ( P <0.001) after haemodialysis. A lesser, but still statistically significant, increase (8-12%) was observed in SCC, AFP and CEA levels ( P <0.05), while the values of the remaining three markers remained unchanged. In conclusion, an increase in some tumour markers was found in our patients after dialysis, a finding which requires further investigation.     

Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration

Summary The serum concentrations of ₁-acid glycoprotein (AAG), albumin (HSA) and non-esterified fatty acids, and the serum binding of tertatolol were measured in four groups of individuals: healthy control subjects (n=24), and patients with inflammation (n=28), and hepatic (n=20) and renal (n=27) insufficiency.Serum binding of tertatolol was increased in patients with inflammation (94.6%), decreased in patients with hepatic insufficiency (88.8%) and it was unchanged in patients with renal insufficiency (92.8%) as compared to controls (92.7%).Multivariate analysis indicated that the changes were mainly related to concomitant changes in AAG concentration, which could account for 57% of intersubject variability in the bound/free ratio, and to a lesser extent in HSA, which accounted for only 4% of the variability in the binding.The data show that the free fraction of the basic drug tertatolol in serum is affected by pathological conditions that cause changes in AAG concentration.     

DWI、IVIM参数与脑胶质瘤患儿肿瘤标志物水平相关性

目的 探究扩散加权成像(diffusion weighted imaging, DWI)、体素不相干运动扩散加权成像(diffusion-weighted imaging of voxel incoherent motion, IVIM)参数与脑胶质瘤患儿肿瘤标志物水平相关性及诊断价值。方法 选取于我院进行诊断的疑似脑胶质瘤患儿89例,以病理检查为金标准,最终确诊脑胶质瘤患儿62例为观察组,其余27例为对照组。所有研究对象均进行DWI技术、IVIM技术检查,酶联免疫吸附实验法检测糖链抗原125(carbohydrate antigen 125,CA125)、表皮生长因子(epidermal growth factor, EGF)、癌胚抗原(carcinoembryonic antigen, CEA)水平,对比不同病情患儿表观弥散系数(apparent dispersion coefficient, ADC)、相对脑血容量(relative cerebral blood volume, rCBV)、真实水分子弥散系数(true water molecular dispersion coe...     

香萱解郁方对血清剥夺诱导HT22细胞损伤模型的神经保护作用

探讨香萱解郁方含药血清对血清剥夺致小鼠海马神经元HT22细胞损伤模型的影响。方法 采用血清剥夺培养HT22细胞建立神经损伤体外模型,实验分为对照组、模型组和中药组［中药组A（含药血清15%浓度）、中药组B（含药血清20%浓度）］,各组血清剥夺12 h后,通过CCK8法检测各组细胞活力,确定15%浓度含药血清干预后细胞的存活率最高,设定为后续实验中药组的药物浓度。免疫荧光染色法检测神经元特异性微管蛋白（β-Tubulin Ⅲ）在各组中的表达,蛋白质免疫印迹法及qPCR法检测脑源性神经营养因子（BDNF）蛋白及其mRNA在各组中的表达。结果 在加药后培养12 h,中药组的细胞活力明显高于对照组与模型组（P＜0.001）。培养24 h,模型组细胞活力较对照组明显下降（P＜0.001）,中药组较模型组明显提高（P＜0.001）。培养36 h,模型组细胞活力较对照组显著下降（P＜0.001）,中药组较模型组明显提高（P＜0.001）。模型组BDNF蛋白含量及 BDNF mRNA表达量较对照组显著降低（P＜0.05,P＜0.001）,模型组少数神经元长出突起;中药组BDNF蛋白含量及BDNF mRNA表达量较模型组显著增加（P＜0.05）,中药组HT22细胞轴突突起长度和分支增加,β-Tubulin Ⅲ阳性表达明显增多。结论 香萱解郁方含药血清对血清剥夺诱导小鼠海马神经元HT22细胞损伤具有神经保护作用,可能与促进BDNF蛋白表达有关     

Soman intoxication-induced changes in serum acute phase protein levels,corticosterone concentration and immunosuppressive potency of the serum

We have studied the effect of soman intoxication on serum acute phase reactants (APR) levels, and the relationship of the APR and corticosterone concentrations and the immunosuppressive activity of the serum. One day after the injection of 1.8 LD₅₀ soman the concentrations of ₂-macroglobulin (₂-MG) and ₁-acid glycoprotein (AGP) in the serum of antidote protected rats increased 4- and 7-fold, respectively, whereas those of hemopexin (Hx), haptoglobin (Hp) and cysteine protease inhibitor (CPI) were two to three times higher than in the controls. A similar magnitude of increase of serum acute phase reactants levels was observed when 0.3 LD₅₀ soman was administered at 24-h intervals over the 5-day period. The relationship of changes in the APR concentration, corticosterone level and immunosuppressive activity of the serum was also comparable to that observed in the acute phase response to tissue injury.     

Studies on the Level of Natural Antibodies Reactive with Various Tumor Cells during Urethane Carcinogenesis in BALB/c Mice

Serum from young normal BALB/c mice was found to contain IgM antibodies able tomediate complement-dependent lysis of certain syngeneic or allogeneic tumor target cells. The titer of such naturally occurring antitumor antibodies (NATA) was found to increase with aging.A longitudinal serological study comparing the cytotoxicity potential of NATA fromnormal and from urethan-treated BALB/c mice was performed. It was found that urethan-treated mice that did not develop primary lung-adenomas within the duration of the experi-ment had significantly lower NATA titers, against one out of 4 target cells assayed, than urethan-treated animals that developed lung adenomas. This difference was evident in two independent experiments. The results suggested that the lower NATA activity of the urethan-treated mice that did not develop tumors existed even before exposure to the carcinogenic insult. This raises the possibility that certain populations could be segregated according to their natural antibody profile into those individuals which will develop primary tumors within a certain period if exposed to a subthreshold amount of carcinogen, and those which will not.